Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 2, 2016, Pages 324-329

  Bregante, Stefania ^a   Dominietto, Alida ^a   Ghiso, Anna ^a   Raiola, Anna Maria ^a   Gualandi, Francesca ^a   Varaldo, Riccardo ^a   Di Grazia, Carmen ^a   Lamparelli, Teresa ^a   Luchetti, Silvia ^a   Geroldi, Simona ^a   Casarino, Lucia ^a   Pozzi, Sarah ^a   Tedone, Elisabetta ^a   Van Lint, Maria Teresa ^a   Galaverna, Federica ^a   Barosi, Giovanni ^b   Bacigalupo, Andrea ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Haploidentical donors; Myelofibrosis; Unrelated donors

Indexed keywords

BUSULFAN; FLUDARABINE; THIOTEPA;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENGRAFTMENT; FAMILY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAPLOIDY; HEMOGLOBIN BLOOD LEVEL; HLA SYSTEM; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOFIBROSIS; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; SIBLING; THROMBOCYTE; UNRELATED DONORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROCEDURES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS; YOUNG ADULT;

EID: 84958559404     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.09.028     Document Type: Article

References (21)

1. Barosi G., Vannucchi A.M., De Stefano V., et al. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. Leuk Res 2014, 38:155-160.
2. Li Z., Gooley T., Applebaum F.R., Deeg H.J. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 2001, 97:2180-2181.
3. Kröger N., Holler E., Kobbe G., et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009, 114:5264-5270.
4. Ballen K.K., Shrestha S., Sobocinski K.A., et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010, 16:358-367.
5. Stübig T., Alchalby H., Ditschkowski M., et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 2014, 28:1736-1738.
6. Klyuchnikov E., El-Cheikh J., Sputtek A., et al. CD34-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant 2014, 20:382-386.
7. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013-1018.
8. Rondelli D., Barosi G., Bacigalupo A., et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105:4115-4119.
9. Deeg H.J., Gooley T.A., Flowers M.E., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102:3912-3918.
10. Scott B.L., Gooley T.A., Sorror M.L., et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012, 119:2657-2664.
11. Gupta V., Malone A.K., Hari P.N., et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2014, 20:89-97.
12. Passamonti F., Cervantes F., Vannucchi A.M., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
13. Bacigalupo A., Soraru M., Dominietto A., et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010, 45:458-463.
14. Raiola A.M., Dominietto A., Ghiso A., et al. Unmanipulated haploidentical bone marrow transplant and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013, 19:117-122.
15. McLornan D.P., Mead A.J., Jakson G., Harrison C.N. Allogeneic stem cell transplantation for myelofibrosis in 2012. Brit J Haematol 2012, 157:413-425.
16. Claudiani S., Marktel S., Piemontese S., et al. Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Hematol Oncol 2014, [Epub ahead of print].
17. Patriarca F., Bacigalupo A., Sperotto A., et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008, 93:1514-1522.
18. Rezvani A.R., McCune J.S., Storer B.E., et al. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biol Blood Marrow Transplant 2013, 19:1033-1039.
19. Sanz J., Boluda J.C., Martín C., et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with haematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 2012, 47:1287-1293.
20. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
21. Kröger N., Giorgino T., Scott B.L., et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. Blood 2015, 125:3347-3350.